Plecanatide in chronic idiopathic constipation and irritable bowel syndrome with constipation: a profile of its use in the USA

Plecanatide (Trulance®), a guanylate cyclase C agonist, is an effective and generally well-tolerated treatment option for adults with chronic idiopathic constipation or irritable bowel syndrome with constipation. It can be administered with or without food, at any time of the day. In phase 3 clinical trials, once-daily plecanatide 3 mg significantly improved stool frequency, stool consistency, clinical symptoms (e.g. straining, abdominal symptoms including pain), health-related quality of life, and treatment satisfaction. Plecanatide is generally well tolerated, with most adverse events being of mild or moderate severity. Consistent with its therapeutic action, the most common adverse event is diarrhea. © 2018, Springer Nature Switzerland AG.